A New Step in Lung Cancer Treatment: Tumor Resection Without Mediastinoscopy

Recent research points to an important development for patients with lung cancer . A European study showed that patients with negative systematic endosonography findings could proceed directly to lung cancer surgery, including tumor resection and lymph node dissection, without confirmatory mediastinoscopy. This offers a less invasive and potentially faster treatment process.

Operable lung cancer means that the tumor can be removed surgically. General health, tumor stage and size help determine operability. Patients with operable disease have the opportunity for complete tumor removal and prevention of further spread through surgery.

Systematic endosonography is described as a noninvasive imaging technique using endoscopic ultrasound (EUS) and endobronchial ultrasound (EBUS) to assess lymph nodes and mediastinal structures. It is important in lung cancer staging. A negative result means no signs of tumor spread to lymph nodes were found during the examination.

*

Mediastinoscopy is a surgical examination of the mediastinum, the central area of the chest. It can confirm whether cancer has spread to lymph nodes.

Study Details

Researchers in the Netherlands and Belgium conducted MEDIASTrial , proposing a new approach: patients with negative systematic endosonography can proceed immediately to tumor resection and lymph node dissection without confirmatory mediastinoscopy.

Understanding N2 Disease

N2 disease is a term used in lung cancer staging. The TNM classification describes tumor size and spread (T), lymph node involvement (N), and distant metastases (M).

N2 disease indicates spread to mediastinal lymph nodes in the middle of the chest. Detecting N2 involvement is important for treatment planning, and immediate surgery is generally not preferred in these patients.

Results

• The study included 346 patients recruited from centers in the Netherlands and Belgium.

• After negative systematic endosonography, patients were divided into two groups:

  • The first included 171 patients undergoing immediate tumor resection and lymph node dissection.
  • The second included 175 patients undergoing tumor resection and lymph node dissection after confirmatory mediastinoscopy.

• The primary aim was to compare unforeseen N2 disease rates after immediate resection with those after confirmatory mediastinoscopy. An 8% noninferiority margin was set.

• Mediastinoscopy detected metastases in 14 of 175 patients (8.0%; 95% confidence interval, 4.8%–13.0%).

• Unforeseen N2 disease was found in 15 of 171 patients undergoing immediate resection (8.8%; 95% confidence interval, 5.4%–14.0%) and 12 of 155 patients in the mediastinoscopy group (7.7%; 95% confidence interval, 4.5%–13.0%). The difference was 1.03%, with an upper difference bound of 7.2% (P for noninferiority=0.0144).

• Serious morbidity or 30-day mortality occurred in 12.9% after immediate resection and 15.4% in the mediastinoscopy group (P=0.4940).

Confirmatory mediastinoscopy after negative systematic endosonography aims to detect previously unrecognized N2 disease. This study, however, shows that patients with negative endosonography can proceed directly to resection and lymph node dissection without this confirmation.

The approach is expected to offer a less invasive, faster treatment process, potentially improving quality of life and comfort for patients with lung cancer.